ALNEV.PA Stock Trades at €0.0004 on EURONEXT After Hours

Neovacs S.A. (ALNEV.PA) trades at €0.0004 on EURONEXT after hours today, reflecting extreme distress in the biotech sector. The Paris-based therapeutic vaccine developer has seen its ALNEV.PA stock collapse over the past year, down 99.99% from prior levels. Trading volume reached 248 million shares, showing active liquidation pressure. The company focuses on Kinoid technology for autoimmune and cancer treatments, but financial metrics reveal severe operational challenges. Meyka AI’s analysis platform tracks ALNEV.PA stock performance across global markets in real time.

ALNEV.PA Stock Price and Trading Activity

Neovacs S.A. trades at just €0.0004 per share, down from €62.0 at its 52-week high. The stock has lost 95.4% year-to-date and 99.99% over the past 12 months. Today’s after-hours session shows relative volume of 16.8%, indicating moderate liquidation despite the extreme price collapse.

Market capitalization sits at just €191, making ALNEV.PA one of the smallest-cap stocks on EURONEXT. The 50-day moving average stands at €0.00101, while the 200-day average is €0.22507, showing a dramatic downtrend. Previous close was €0.0004, with today’s range between €0.0002 and €0.0006.

Financial Metrics and Valuation Concerns

Neovacs reports negative earnings per share of -€221.36, making traditional valuation metrics meaningless. The price-to-sales ratio of 0.0005 appears cheap, but reflects a company burning cash with minimal revenue generation. Book value per share is €103.50, yet the stock trades at just 0.0000039 times book value.

Operating cash flow per share is -€20.64, indicating the company consumes cash to fund operations. Free cash flow per share is -€21.09, showing no path to profitability without external funding. The current ratio of 0.63 signals liquidity stress, as current liabilities exceed current assets by a significant margin.

Market Sentiment and Technical Signals

Technical indicators flash severe weakness across ALNEV.PA stock analysis. The Relative Strength Index (RSI) at 33.83 suggests oversold conditions, yet the stock continues lower. The Average Directional Index (ADX) reads 43.69, confirming a strong downtrend with no reversal signals present.

Money Flow Index (MFI) at 9.56 indicates extreme oversold conditions rarely seen in liquid markets. The Commodity Channel Index (CCI) at -77.78 shows maximum bearish momentum. On-Balance Volume is deeply negative at -446 million, reflecting sustained selling pressure from institutional and retail investors alike.

Meyka AI Rating and Investment Grade

Meyka AI rates ALNEV.PA with a grade of C+, suggesting a HOLD recommendation despite severe distress signals. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score of 58.52 reflects mixed signals between valuation metrics and operational performance.

The company’s biotech pipeline includes IFNa Kinoid in Phase IIb trials for systemic lupus erythematosus and VEGF-Kinoid in preclinical development. However, negative cash flow and minimal revenue make clinical progress irrelevant without capital infusion. These grades are not guaranteed and we are not financial advisors.

Final Thoughts

ALNEV.PA stock trades at extreme distress levels on EURONEXT, reflecting years of clinical setbacks and cash burn. The €0.0004 price represents a 99.99% decline from prior peaks, with market cap of just €191. Neovacs S.A. faces an existential funding crisis, as negative cash flow and minimal revenue cannot sustain operations. Technical indicators show maximum bearish momentum with no reversal signals. Track ALNEV.PA on Meyka for real-time updates on this distressed biotech name. Investors should recognize this as a speculative, high-risk situation requiring extreme caution and thorough due diligence before any consideration.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.